(0.76, 3.01) (0.40, 3.94) (0.33, 1.65) (0.32, 2.38) (0.37, 2.73) (0.24, 1.07) (0.18, 1.18) 89% 66% 24% 35% 50% 4% 5% Corticosteroids 3.72* 3.05* 1.84* 2.01 2.42* 1.22 1.11 2.44* (2.24, 5.89) (1.09, 8.41) (1.03, 3.17) (0.97, 4.66) (1.08, 5.51) (0.83, 1.84) (0.52, 2.29) (1.21, 4.82) >99% 98% 98% 97% 98% 86% 61% >99% Appendix Table : Results of sensitivity analysis of network meta-analysis using combined doses of mesalamine and budesonide for the induction of remission of patients disease with Crohn’s Intervention COMPARATOR Odds ratio (95% Credible interval)* Placebo Mesalamine Sulfasalazine Budesonide - Mesalamine 1.84* (1.25, 2.77) >99% Sulfasalazine 1.52 0.83 - (0.82, 2.68) (0.42, 1.57) 92% 26% - Budesonide 2.90* 1.57* 1.91* (1.98, 4.30) (1.06, 2.32) (1.04, 3.61) >99% 99% 98% Corticosteroid 3.57* 1.94* 2.35* 1.23 (0.88, 1.73) (2.40, 5.41) (1.28, 2.90) (1.34, 4.31) >99% >99% >99% 90% Appendix Table : Results of sensitivity analysis of network meta-analysis using only studies which define lower and upper limits for CDAI ranges (i.e., CDAI 150-40) for the induction of remission of patients disease with Crohn’s Intervention COMPARATOR
(0.76, 3.01) 89% (0.40, 3.94) 66% (0.33, 1.65) 24% (0.32, 2.38) 35% (0.37, 2.73) 50% (0.24, 1.07) 4% (0.18, 1.18) 5% Corticosteroids 3.72* (2.24, 5.89) >99% 3.05* (1.09, 8.41) 98% 1.84* (1.03, 3.17) 98% 2.01 (0.97, 4.66) 97% 2.42* (1.08, 5.51) 98% 1.22 (0.83, 1.84) 86% 1.11 (0.52, 2.29) 61% 2.44* (1.21, 4.82) >99% Appendix Table : Results of sensitivity analysis of network meta-analysis using combined doses of mesalamine and budesonide for the induction of remission of patients with Crohn’s disease Intervention COMPARATOR Odds ratio (95% Credible interval)* Placebo Mesalamine Sulfasalazine Budesonide Mesalamine 1.84* (1.25, 2.77) >99% - Sulfasalazine 1.52 (0.82, 2.68) 92% 0.83 (0.42, 1.57) 26% - Budesonide 2.90* (1.98, 4.30) >99% 1.57* (1.06, 2.32) 99% 1.91* (1.04, 3.61) 98% - Corticosteroid 3.57* (2.40, 5.41) >99% 1.94* (1.28, 2.90) >99% 2.35* (1.34, 4.31) >99% 1.23 (0.88, 1.73) 90% Appendix Table : Results of sensitivity analysis of network meta-analysis using only studies which define lower and upper limits for CDAI ranges (i.e., CDAI 150-40) for the induction of remission of patients with Crohn’s disease Intervention COMPARATOR
IBD_2016_12_28_KAPLAN_IBD-D-16-00226_SDC1.docx